Clinical Trial: Phase 1 PK Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients

U.S., Sept. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07802730) titled 'Phase 1 PK Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients' on Aug. 29.

Brief Summary: This is a phase 1, single-dose, 2-period crossover study in healthy volunteers to compare the systemic pharmacokinetic (PK) profile of inhaled AERO-002 versus inhaled active comparator product.

Study Start Date: Sept., 2026

Study Type: INTERVENTIONAL

Condition: COPD (Chronic Obstructive Pulmonary Disease)

Intervention: DRUG: AERO-002 (60 mcg)

Single dose, administered via inhalation using a standard jet nebulizer

DRUG: Glycopyrrolate (18 mcg)

Single dose, administered via inhalation using pMD...